CSL reports net profit after tax for six months ending 31 December 2023

CSL Limited announced a reported net profit after tax of $1.90 billion1 for the 6 months that ended 31 December 2023, up 20% on a constant currency basis.3

Underlying profit (NPATA) was $2.02 billion,1,2 up 13% on a constant currency basis to $2.06 billion.1,2,3

Dr Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “Our strong first-half result for the 2024 financial year was driven by CSL Behring’s exceptional performance across its portfolio, especially immunoglobulins.”

Specialty products sales of $976 million were up 6%3, led predominately by demand for Kcentra and Haegarda.

Haegarda, a therapy for patients with Hereditary Angioedema, increased 9%, driven by the continued shift from on-demand to prophylaxis treatment and a strong performance in the UK and Europe.

Additionally, garadacimab (anti-FXIIa), for HAE, was filed for regulatory approval in the US and EU.


  1. Attributable to CSL shareholders
  2. Statutory net profit after tax (NPAT) before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and the unwind of the inventory fair value uplift.
  3. Constant currency (CC) removes the impact of exchange rate movements, facilitating the comparability of operational performance. For further detail refer to CSL’s Financial Statements for the Half Year ended December 2023(Directors Report).

(Source: CSL)